{"brief_title": "A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)", "brief_summary": "This study is to evaluate the safety, tolerability, and immune response of an investigational vaccine in preadolescent and adolescent boys and girls for the prevention of Human Papilloma Virus (HPV).", "detailed_description": "The original base protocol (V501-018)(NCT00092547) was extended in amendments V501-018-05 and -06 to provide 37 months of follow-up. Additionally, subjects in the Placebo Group during the base study were given 3 doses of open-label GARDASIL\u2122 (V501) at Months 30, 32, and 36. The study was extended again in amendment V501-018-10(NCT00092547), titled \"A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age\" to allow a follow-up period to Month 126.", "condition": "Papillomavirus Infections", "intervention_type": "Biological", "intervention_name": "Comparator: Placebo", "description": "0.5 mL intramuscular injection of placebo", "arm_group_label": "Placebo in Base Study", "other_name": "GARDASIL\u2122", "criteria": "Inclusion Criteria: - Healthy adolescents and preadolescents with no prior sexual history Exclusion Criteria: - Subjects with compromised immune system or have a history of severe allergic reaction", "gender": "All", "minimum_age": "9 Years", "maximum_age": "15 Years", "healthy_volunteers": "Accepts Healthy Volunteers", "id": "NCT00092547.xml"}